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Abstract
Background: Evaluation of responses to treatment for metastatic castration-resistant
prostate cancer (mCRPC) remains challenging. Consensus criteria based on prostate-
specific antigen (PSA) and clinical and radiologic biomarkers are inconsistently utilized.
Circulating tumor cell (CTC) counts can inform prognosis and response, but are not
routinely used.
Objective: To evaluate the use of biomarkers and trends in clinical decision-making in
current mCRPC treatment.
Design, setting, and participants: A 23-part online questionnaire was completed by
physicians treating mCRPC.
Outcome measures and statistical analysis: Results are presented as the proportion (%)
of physicians responding to each of the options. We used x2 and Fisher’s tests to compare
differences.
Results and limitations: A total of 118 physicians (22.1%) responded. Of these, 69.4%
treated 50 mCRPC patients/year. More physicians administered four or fewer courses
of cabazitaxel (27.9%) than for docetaxel (10.4%), with no signiﬁcant difference in the
number of courses between bone-only disease and Response Evaluation Criteria in Solid
Tumours (RECIST)–evaluable disease. Some 74.5% of respondents considered current
biomarkers useful for monitoring disease, but only 39.6% used the Prostate Cancer
Working Group (PCWG2) criteria in clinical practice. PSA was considered an important
biomarker by 55.7%, but only 41.4% discarded changes in PSA before 12 wk, and only
39.4% were able to identify bone-scan progression according to PCWG2. The vast
majority of physicians (90.5%) considered clinical progression to be important for
switching treatment. The proportion considering biomarkers important was 71.6%
for RECIST, 47.4% for bone scans, 23.2% for CTCs, and 21.1% for PSA. Although 53.1%
acknowledged that baseline CTC counts are prognostic, only 33.7% would use CTCit
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Conclusions: A signiﬁcant proportion of physicians discontinue treatment for mCRPC
before 12 wk, raising concerns about inadequate response assessment. Many physicians
ﬁnd current biomarkers useful, but most rely on symptoms to drive treatment switch
decisions, suggesting there is a need for more precise biomarkers.
Patient summary: In this report we analyse the results of a questionnaire evaluating tools
for clinical decision-making completed by 118 prostate cancer specialists. We found that
most physicians favour clinical progression over prostate-speciﬁc antigen or imaging, and
that criteria established by the Prostate Cancer Working Group are not widely used.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The past decade has seen an increase in the therapeutic
armamentarium against metastatic prostate cancer, with
agents proving survival benefit both in the castrate-
resistant (mCRPC) [1–7] and castration-naı¨ve stages [8,9]
of the disease. This increased availability of treatment
options necessitates improved biomarkers to determine
treatment responses more rapidly and facilitate optimised
decisions on therapeutic sequencing [10].
Prostate-specific antigen (PSA), bone scans, and Re-
sponse Evaluation Criteria in Solid Tumours (RECIST)
criteria are commonly utilized to evaluate responses and
are recommended as outcome measures by the Prostate
Cancer Working Group (PCWG2) for clinical trials
[11]. However, these biomarkers have significant limita-
tions. In particular, PSA and bone scans do not allow early
response assessment, and none of the biomarkers provide
patient-level surrogates of clinical benefit [12,13]. This
challenge is compounded by the lack of RECIST-evaluable
disease in a substantial proportion of patients [14]. For daily
clinical practice, existing guidelines do not recommend
specific treatment monitoring, an issue addressed by the
Advanced Prostate Cancer Consensus conference [15].
The lack of adequate biomarkers may impact the dose
intensity of chemotherapy and other anticancer (hormonal,
radiopharmaceutical) agents administered in daily clini-
cal practice. The fact that determining disease progres-
sion in the absence of clear clinical deterioration is
impossible before 12 wk (owing to the possibility of an
early PSA or bone scan ‘‘flare reaction’’) in patients with
no RECIST-evaluable disease may contribute to both the
administration of more chemotherapy cycles to patients
with bone-only disease (overtreatment) and a higher
reliance on PSA changes for early treatment discontinua-
tion (undertreatment).
Circulating tumour cell (CTC) counts are prognostic and
are associated with treatment response in mCRPC patients,
with recent studies indicating value as a patient-level
surrogate of survival [16,17]. Increasing evidence suggests
that CTCs could be utilised to monitor disease progression in
mCRPC [18]. However, CTC use is largely limited to
academic centres in the setting of clinical trials.
We conducted an online survey of physicians treating
mCRPC. The survey focused on how physicians make
treatment switch decisions, opinion on response indicators,
utilisation of PCWG2 criteria in routine practice, and the
value of CTC counts to guide treatment switch decisions.
The results will help to inform the design of an internationalPlease cite this article in press as: Lorente D, et al. Interrogating Me
institutional Survey. Eur Urol Focus (2016), http://dx.doi.org/10.1trial and health economic evaluation to improve treatment
switch decisions for mCRPC patients to improve outcomes,
decrease overtreatment, and maximise resource utilisation.
2. Materials and methods
A 23-part online questionnaire, divided in four sections as outlined
below, was compiled by the authors (Supplementary Fig. 1):
1. General questions on clinical practice.
2. Familiarity with progression criteria for currently established
biomarkers.
3. CTCs and their assessment in patients with advanced prostate cancer.
4. Clinical decision-making using response indicators.
E-mails inviting participation in the survey were sent to 485 UK
investigators participating in urologic cancer clinical trials, 29 physician
members of the GU Group of the Swiss Group for Clinical Cancer
Research, and 20 practising prostate cancer physicians in Australia and
New Zealand. A link to the web-based survey (created with Survey-
Monkey) was included.
2.1. Statistical analyses
Descriptive statistics were used; the proportion (%) of physicians
responding to each option is presented. Physicians were classiﬁed
according to the number of patients they treated (50 vs <50 patients/
year) or recruited to clinical trials (25% vs <25%), and the number of
cycles of docetaxel/cabazitaxel prescribed (4, 5–6, 7 cycles). No pre-
existing evidence was used in choosing classiﬁcation cutoff values.
Proportions were compared using a x2 test or Fisher’s exact test (for cell
frequencies 5). A p value of 0.05 was set as the limit for statistical
signiﬁcance. No adjustment for multiple testing was performed. SPSS
version 21 (IBM IBM, Armonk, NY, USA) was used.
3. Results
3.1. Participant characteristics and their clinical practice
Between November 21, 2014 and December 18, 2014,
118 practising prostate cancer physicians (22.1%) replied.
Sections 1, 2, 3, and 4 were completed by, 111, 106, 98, and
89 physicians, respectively. Most respondents (77.1%)
practised in the UK. Nearly 70% treated 50 mCRPC
patients/year (Table 1). Most reported prescribing 7–10
courses of docetaxel and 5–6 cycles of cabazitaxel (Fig. 1);
there was no difference in the number of courses of either
docetaxel ðpðx22Þ ¼ 0:519Þ or cabazitaxel ðpðx22Þ ¼ 0:814Þ
administered to patients with RECIST-evaluable disease
compared to patients with bone-only disease. Physicianstastatic Prostate Cancer Treatment Switch Decisions: A Multi-
016/j.euf.2016.09.005
Table 1 – Participant characteristics
Question (number of responses) n (%)
Q1: Specialty (n = 118)
Oncologist 100 (84.7)
Urologist 17 (14.4)
Other 1 (0.8)
Q2: Practice location (n = 118)
UK 91 (77.1)
Europe (non-UK) 16 (13.6
Australia/New Zealand 11 (9.3)
Q3: Number of mCRPC patients
treated per year (n = 111)
<10 3 (2.7)
10–49 31 (27.9)
50–99 48 (43.2)
100 29 (26.1)
Q4: Percentage of mCRPC patients
entered into clinical trials (n = 111)
None 6 (5.4)
<25% 53 (47.7)
25–49% 38 (34.2)
50–74% 12 (10.8)
75% 2 (1.8)
mCRPC = metastatic castration-resistant prostate cancer.
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in patients with both RECIST-evaluable and bone-only
disease ðpðx22Þ < 0:001Þ. Physicians with larger patient
practices prescribed more courses of chemotherapy (Sup-
plementary Table 1).
3.2. Evaluation of currently available response biomarkers
Current guidelines provide little instruction on the evalua-
tion of response to treatment in mCRPC; this is particularly
challenging in patients with only bone metastases and no
other measurable disease [15,19]. PCWG2 progression
criteria (Supplementary Table 2) are mainly used among
patients treated within clinical trials. We evaluated the
opinion of physicians on currently available biomarkers
(PSA, bone scan, and CTCs) for monitoring response. SomeFig. 1 – Number of cycles of chemotherapy administered to patients with Resp
bone-only metastatic castration-resistant prostate cancer (mCRPC). The figure 
cabazitaxel do you prescribe, on average, to mCRPC patients with RECIST-evalu
Please cite this article in press as: Lorente D, et al. Interrogating Me
institutional Survey. Eur Urol Focus (2016), http://dx.doi.org/10.179 respondents (74.5%) rated these as useful (71.7%) or very
useful (2.8%). Only 39.6% reported using PCWG2 criteria
most or all of the time, and 27.3% reported rarely or never
using the criteria (Table 2). Physicians recruiting more
patients to trials were more likely to use PCWG2 frequently
(56% vs 25%; pðx22Þ ¼ 0:001Þ = 0.001; Supplementary
Table 3).
3.2.1. PSA
A total of 59 respondents (55.7%) reported that PSA was a
useful/very useful biomarker for monitoring response to
treatment (Table 2). We asked participants to identify PSA
progression in graphical examples showing consecutive PSA
values to evaluate their ability to utilize PCWG2 criteria.
Only 41.4% of physicians correctly recognised that at least
12 wk are required to define PSA progression (Fig. 2A). Most
physicians (84.8%) correctly identified that a 25% increase
from the nadir value (confirmed by a second value at least
3 wk later) constituted progression (Fig. 2B). Some 90.9%
failed to recognise that PSA progression holds even if the
confirmatory second value is lower than the first, providing
both values show a 25% increase from the nadir (Fig. 2C).
Only two physicians (2.0%) answered all three questions
correctly.
3.2.2. Bone scintigraphy
PCWG2 criteria define bone scan progression as a minimum
of two new lesions, with new lesions observed at the first
12-wk reassessment requiring a confirmatory scan (Sup-
plementary Table 2). When respondents were asked to
choose from a number of definitions of bone scan
progression (selecting more than one was permitted), only
39.4% answered the correct option (as per PCWG2) and
discarded the incorrect options, indicating diversity in bone
scan interpretation.
3.2.3. CTCs
Some 98% of respondents were familiar with the concept of
CTCs, but only 53.1% recognised that baseline CTCs haveonse Evaluation Criteria in Solid Tumours (RECIST)–evaluable disease and
summarises replies for Questions 5–8 (‘‘How many cycles of docetaxel/
able/bone only disease?’’).
tastatic Prostate Cancer Treatment Switch Decisions: A Multi-
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Table 2 – Evaluation of currently available biomarkers, CTCs and use of Prostate Cancer Working Group (PCWG2) criteria in mCRPC
Question (number of responses) n (%)
Q9: Suitability of currently available biomarkers (PSA, bone scans, CTCs) in monitoring disease in mCRPC (n = 106)
Very useful 3 (2.8)
Useful 76 (71.7)
Not very useful 25 (23.6)
Poor 2 (1.9)
Q11: Suitability of PSA as a chemotherapy response marker in mCRPC (n = 106)
Very useful 3 (2.8)
Useful 56 (52.8)
Not very useful 44 (41.5)
Poor 3 (2.8
Q10: Use of PCWG2 criteria for decision-making when treating patients with mCRPC (n = 106)
Always 3 (2.8)
Mostly 39 (36.8)
Sometimes 35 (33)
Rarely 12 (11.3)
Never 17 (16)
Q14: Familiar with the concept of CTCs (n = 98)
Yes 96 (98)
No 2 (2)
Q15: Baseline number of CTCs at start of chemotherapy is prognostic for overall survival in mCRPC (n = 98)
Yes 52 (53.1)
No 0 (0)
Unsure 46 (46.9)
Q16–17: Change in number of CTCs is associated with response in mCRPC during (n = 98): Chemotherapy
Yes 53 (54.1)
No 0 (0)
Unsure 45 (45.9)
Abiraterone
Yes 49 (50)
No 0 (0)
Unsure 49 (50)
Q18: Challenges associated with use of CTCs in prostate cancer (n = 98)
Cost 73 (74.5)
Lack of/uncertainty about prognostic signiﬁcance 43 (43.9)
Lack of/uncertainty about predictive information on treatment response 57 (58.2)
Difﬁculty in interpreting changes in CTC number 41 (41.8)
Poor access to CTC enumeration technology 83 (84.7)
Other 4 (4.1)
Q20: Likelihood of switching or stopping chemotherapy in an asymptomatic mCRPC patient with PSA increase at 12 wk and no radiologic progression (n = 95)
Deﬁnitely 0 (0)
Likely 16 (16.8)
Unlikely 70 (73.7)
Deﬁnitely not 9 (9.5)
Q21: Likelihood of switching or stopping abiraterone or enzalutamide in an asymptomatic mCRPC patient with PSA increase at 12 wk and no radiologic
progression (n = 95)
Deﬁnitely 0 (0)
Likely 9 (9.5)
Unlikely 68 (71.6)
Deﬁnitely not 18 (18.9)
Q23: Likelihood of using CTC changes alone, independently of PSA or bone scan ﬁndings, in guiding decision-making to switch or stop therapy in an mCRPC
patient with bone-only disease (n = 89)
Deﬁnitely 1 (1.1)
Likely 29 (32.6)
Unlikely 55 (61.8)
Deﬁnitely not 4 (4.5)
CTC = circulating tumour cell; mCRPC = metastatic castration-resistant prostate cancer; PSA = prostate-speciﬁc antigen.
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dents were aware that a post-treatment change in CTCs was
associated with outcome in patients treated with abirater-
one and chemotherapy, respectively (Table 2).
Major challenges identified by respondents as currently
limiting the use of CTCs in prostate cancer were assay cost
(74.5%), poor access to CTC enumeration tests (84.7%), and
uncertainty over their clinical utility in response assess-
ment (58.2%; Table 2).Please cite this article in press as: Lorente D, et al. Interrogating Me
institutional Survey. Eur Urol Focus (2016), http://dx.doi.org/10.13.3. Clinical decision-making in CRPC
According to PCWG2, clinical progression is defined as
worsening pain and analgesic use, deteriorating quality of
life, urinary or bowel compromise, or a need for new
anticancer therapy. Of these, only worsening pain is
associated with outcome in prospective clinical trials
[20]. Almost all physicians (90.5%) considered clinical
progression to be important for driving treatment switches.tastatic Prostate Cancer Treatment Switch Decisions: A Multi-
016/j.euf.2016.09.005
Fig. 2 – Evaluation of prostate-specific antigen (PSA) progression criteria. The figure summarises replies for Question 12. Participants were shown three
different PSA biomarker scenarios for patients with bone-only disease. The percentage of participants who believed the scenario corresponded to PSA
progression is shown in the pie charts. Correct response: (A) No; (B) Yes; (C) Yes.
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sion to be important, and only 23.2% and 21.1% felt CTC and
PSA progression to be important, respectively.
Overall, 55.7% considered PSA useful/very useful in
guiding therapy, but only 21.1% considered it important for
decision-making (Fig. 3). Physicians who considered PSA
and bone scans important/very important for decision-
making did not have a better understanding of response
criteria (Supplementary Table 4). Only 30% of physicians
who considered PSA important/very important in guidingPlease cite this article in press as: Lorente D, et al. Interrogating Me
institutional Survey. Eur Urol Focus (2016), http://dx.doi.org/10.1treatment switches acknowledged that at least 12 wk is
needed to define PSA progression (Supplementary Table 4).
In the case of an asymptomatic mCRPC patient with a
rising PSA at 12 wk but no evidence of radiologic
progression, most physicians were unlikely to switch/stop
chemotherapy (83.2%) or abiraterone/enzalutamide (90.5%).
Only 33.7% of respondents were ready to use CTC changes
alone, independently of PSA or bone scans, to guide
switching/stopping therapy in patients with bone-only
disease; among those who acknowledged the value oftastatic Prostate Cancer Treatment Switch Decisions: A Multi-
016/j.euf.2016.09.005
Fig. 3 – Importance of different biomarkers in clinical decision-making (stopping therapy) in metastatic castration-resistant prostate cancer. The figure
summarises replies for Question 19. Participants were asked to rank each of the different types of disease progression listed from 1 (extremely
important) to 6 (not at all important) in their clinical decisions to switch or stop therapy. RECIST = Response Evaluation Criteria in Solid Tumours;
PSA = prostate-specific antigen; CTCs = circulating tumour cells.
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Of those who were likely/very likely to switch on CTC
changes alone independently of PSA or bone scans, a
larger proportion were physicians who felt that currently
available biomarkers are not very useful/poor in moni-
toring disease (p = 0.03; Supplementary Table 5). Among
those who were unlikely/unwilling to switch on CTC
changes alone, 57.6% cited uncertainty over predictive
information on treatment response as a challenge in use
of CTCs, with 52.5% and 42.4% citing uncertainty over
prognostic significance and difficulty in interpreting CTC
changes, respectively.
3.4. Treatment switches in mCRPC
The final part of the questionnaire asked respondents to
consider scenarios involving clinically stable mCRPC
patients with bone-only disease. For a >25% PSA rise but
a CTC decline to <5 cells/7.5 ml (‘‘favourable’’ CTC conver-
sion) and a stable bone scan at 12 wk, 92.1% of respondents
would not switch/stop therapy (Fig. 4A). The proportion fell
to 68.5% if the bone scan showed increased tracer uptake
but no new lesions (Fig. 4B). For a 50% fall in PSA but a CTC
rise to 5 cells/7.5 ml (‘‘unfavourable’’ CTC conversion) at
12 wk and stable disease according to a bone scan, only
11.2% would switch/stop therapy (Fig. 4C). For a 50% PSA
decline and CTC conversion from ‘‘unfavourable’’ to
‘‘favourable’’ count at 12 wk, but two new lesions on a
bone scan, most respondents (70.8%) reported they would
not switch/stop therapy (Fig. 4D).
Respondents who believed that post-treatment CTC
changes were associated with treatment response were
more likely to switch/stop therapy on CTC progression as in
Figure 4C (p = 0.023), and were more likely to continuePlease cite this article in press as: Lorente D, et al. Interrogating Me
institutional Survey. Eur Urol Focus (2016), http://dx.doi.org/10.1treatment with CTC response as in Figure 4B (p = 0.003) and
Figure 4D (p = 0.005; Supplementary Table 3).
4. Discussion
It is imperative that more precise response biomarkers that
can guide more rapid identification of drug resistance and
treatment termination are developed to minimise the
overtreatment of patients with ineffective therapies,
decrease the toxicity of ineffective treatment, and maximize
the utilisation of resources. We conducted this survey to
evaluate current practice in clinical decision-making by
physicians specialised in the treatment of CRPC. Our results
highlight difficulties in the application of current biomark-
ers in the treatment of advanced prostate cancer in daily
clinical practice.
Are physicians giving too much chemotherapy, or too
little? The optimum number of chemotherapy courses is
unclear. In the TROPIC trial, although a maximum number
of ten cycles of chemotherapy was allowed, a median of six
courses was reported, and 28% of patients completed ten
courses [7]. This is similar to numbers reported in
expanded-access programmes [21,22]. In TAX-327, in
which the number of cycles of docetaxel was not limited
to ten, the median number of cycles in the three-weekly
docetaxel arm was 9.5 [23]. Our survey, however, indicates
that a significant number of physicians discontinue
treatment before four courses (12 wk) of treatment; this
is especially true for cabazitaxel. According to our survey,
early discontinuation does not appear to be related to
radiologic disease progression, since no difference in
the number of chemotherapy courses between RECIST-
evaluable and bone-only disease was reported.tastatic Prostate Cancer Treatment Switch Decisions: A Multi-
016/j.euf.2016.09.005
Fig. 4 – Decision-making for different biomarker scenarios. The figure summarises replies for Question 22. Participants were shown four different
biomarker scenarios combining prostate-specific antigen (PSA), circulating tumor cells (CTCs), and bone scan findings for clinically stable patients. The
proportion of participants who would switch or stop therapy at 12 wk is shown in the pie charts.
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criteria? In our survey, although most physicians consider-
ing currently available biomarkers (74.5%), and PSA in
particular (55.6%), to be useful for monitoring disease,
knowledge of the specific PCWG2 criteria is suboptimal.
PCWG2 requires a confirmatory value at least 3 wk after a
first progressing PSA, and recommends discarding any early
(before 12 wk) PSA increase owing to the possibility of PSA
‘‘flare’’, reported in 16.7% of patients in TAX-327 [24]. In our
survey, many physicians failed to acknowledge the possi-
bility of a PSA flare in evaluating PSA progression.
Concerns regarding the interpretation of bone-scan
imaging were also identified. Only around 40–60% of
mCRPC patients are evaluable according to RECIST, with
many patients having bone-only disease [14]. PCWG2
criteria indicate that bone scans can only be used for the
assessment of progression and not response. New lesions at
the first 12-wk assessment require a confirmatory scan,
since early bone-scan ‘‘flare’’ is not uncommon [25]. Only
39.4% of respondents followed the PCWG2 definition of
bone scan progression, despite recent studies indicating an
association between radiographic progression-free survival
(combining a bone scan and RECIST) and survival in the
COU-302 phase 3 trial [26].
These findings suggest that decisions to switch treat-
ment are challenging for physicians treating advanced
prostate cancer. PCWG2 guidelines acknowledge difficulties
in assessing progression according to clinical symptoms
alone because of ‘‘subjectivity’’ [11]; however, this was
overwhelmingly acknowledged as the most important
determinant of disease progression in routine practice.
RECIST criteria ranked second in importance, despite being
useful for only some patients. Interestingly, only 39.6%
commonly use PCWG2 criteria for clinical-decision making.
When confronting physicians with clinical scenarios based
on CTC, PSA and bone scan information no significant
predominance of one biomarker was found. Physicians
generally continued treatment in the face of ‘‘contradictory’’
biomarker information (ie, rising CTCs with falling PSA;
falling CTCs with rising PSA; or falling CTCs and PSA with
new lesions on bone scan), for which current European
Association of Urology and European Society for Medical
Oncology guidelines do not offer clear recommendations on
optimal decision-making. Importantly, we observed no
significant differences in the familiarity with PSA or bone
scan progression criteria (questions 12 and 13), the
importance of each of the biomarkers in the decision to
switch or stop therapy (question 19), or the likelihood of
switching or stopping in the face of the different proposed
biomarker scenarios (question 20) between physicians
treating in high-volume centres (50 patients/yr) and
those in low-volume centres (<50 patients/yr). These data
suggest a need for more precise biomarkers to report on
response and progression, since patients today appear to
continue receiving treatment despite biomarkers indicating
a lack of response.
CTC count holds promise as a response biomarker, with
well-established prognostic utility that has been validated
prospectively with chemotherapy [16,27], abiraterone [17],Please cite this article in press as: Lorente D, et al. Interrogating Me
institutional Survey. Eur Urol Focus (2016), http://dx.doi.org/10.1and enzalutamide [28]. A combination of lactate dehydro-
genase and CTCs is a patient-level surrogate of survival [17],
and post-treatment changes are robustly associated with
outcome [29,30]. Moreover, CTC counts have greater
sensitivity and specificity and inform on outcome earlier
than changes in PSA do [30,31]. However, only half of the
responding physicians were familiar with available CTC
data, with very few prepared to stop abiraterone (9.5%) or
chemotherapy (16.8%) on the basis of CTC progression.
Nonetheless, physicians cognisant of available CTC data
were more willing to guide treatment according to CTC
changes. Cost was reported as a major caveat to the routine
use of CTCs, although most of this could be easily recouped
by earlier discontinuation of ineffective treatment.
We acknowledge a number of limitations to our study.
The return rate was 22.1%, and not all physicians completed
the entire survey. Reasons for not completing the survey are
unknown, although this could be related to the lack of
compensation offered. Furthermore, no distinction was
made between academic and nonacademic centres, and no
comparison was made between UK-based and non–UK-
based physicians. To maximise the yield of information and
study participants, the size of the questionnaire included
only three questions on biomarker criteria, which may be
insufficient to fully evaluate physician knowledge.
5. Conclusions
In conclusion, our data indicate that more precise response
biomarkers and physician education are needed to interro-
gate outcome in daily clinical practice in mCRPC, and that it
is likely that many patients are being over- and under-
treated. Many physicians rely on the highly subjective
reporting of symptoms for treatment switch decisions.
Physician education on these challenges, and established
working group criteria, are needed, as are prospective trials
to clinically qualify biomarker utility, improve treatment
switch decisions and patient outcome as well as change
clinical practice.
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